Sleepless at Scripps: An Inpatient White Noise Study
Primary Purpose
White Noise, Sleep, Sleep Fragmentation
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Active white noise
Inactive white noise
Sponsored by
About this trial
This is an interventional other trial for White Noise
Eligibility Criteria
Inclusion Criteria:
- Over 18 years old
- Admitted to inpatient internal medicine service for at least 3 nights
Exclusion Criteria:
-
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Night A active white noise
Night B inactive white noise
Arm Description
Patients receiving active level of white noise on night A
Patients will receive a lower Level of white noise on night B. Termed "inactive," because do not expect the level to have a noticeable change in sound level changes, and thus sleep.
Outcomes
Primary Outcome Measures
Sound level changes ≥ 17.5 dB
Change in sound level changes ≥ 17.5dB between inactive and active white noise intervention. This will be using sound level measurements obtained from sound meters placed in patient rooms
Sleep duration
Measured between patients receiving active vs. inactive white noise in minutes using wrist-worn actigraphy devices
Sleep fragmentation
Measured using mean and median sleep bout duration from actigraphy devices in patients receiving active vs. inactive white noise.
Subjective sleep quality
Measured using Richards Campbell Sleep Questionnaire. Assesses subjective sleep in patients who received active white noise. vs. inactive white noise.
Secondary Outcome Measures
Delirium Incidence
Measured using bCAM. Comparing rates of delirium incidence between patients receiving active vs. inactive white noise.
Morning blood glucose
Measured using morning metabolic panels OR point-of-care glucose testing.
Morning blood pressure reading
Measured using standard of care vital signs, both systolic and diastolic measurements.
Delirium incidence based on sleep fragmentation
Measured using bCAM. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have a higher incidence of delirium compared to those with lower levels of sleep fragmentation.
Morning blood pressure based on sleep fragmentation
Measured using standard morning vital signs. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have higher systolic/diastolic blood pressure readings compared to those with lower levels of sleep fragmentation.
Morning blood glucose based on sleep fragmentation
Measured using standard morning metabolic panel OR point-of-care glucose testing. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have higher morning blood glucose readings compared to those with lower levels of sleep fragmentation.
Opioid use
Measured using morphine milligram equivalent totals over the white noise testing period. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have more opioid use compared to those with lower levels of sleep fragmentation.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05475262
Brief Title
Sleepless at Scripps: An Inpatient White Noise Study
Official Title
Sleepless at Scripps: The Use of White Noise to Increase Sleep Duration in Hospitalized Patients, a Prospective Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 28, 2022 (Anticipated)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
February 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Scripps Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Sleep is an important part of the healing process, and patients admitted to the hospital often report poor sleep. Patients have difficulty not only falling sleep, but also staying asleep. Prior studies show that hospital noise may be a contributing factor, and in particular, sound level changes (which refers to an increase in sound above the background/baseline noise level) may cause arousals from sleep. Based on preliminary data, this study aims to use white noise to reduce the number of relevant sound level changes that occur during a night of sleep in the hospital. Using a randomized, cross-over design, the investigators aim to enroll 45 inpatient adults (age ≥ 65 years) to receive "active," white noise (white noised played at 57-60 decibels) on one night of their stay, and "inactive," white noise (white noise played at 45-50 decibels) on an alternate night. Three major primary outcomes will be investigated - 1) objective sleep duration as measured using actigraphy, 2)objectively measured sleep fragmentation using actigraphy, and 3) subjective sleep quality using the Richards Campbell Sleep Questionnaire. Secondary outcomes will include sound level changes in the room (measured using sound meters), as well as morning blood glucose (for diabetic/prediabetic patients) and blood pressure measurements. Delirium will be measured twice daily through the inpatient stay in a secondary analysis to compare levels of sleep fragmentation to delirium incidence.
Detailed Description
Methods (Intervention and Study Design). This study will use a randomized cross-over framework. The investigators have chosen a design that will allow for pair-wise comparisons of sleep for each participant. Participants will receive white noise on the 2nd (night A) and 3rd (night B) night of the hospital stay. Patients will be randomized to receive inactive white noise (45-50 dB) on either night A or B and active white noise (57-60 dB) on the alternate night. An unblinded study staff member will dispense a machine calibrated to either active or inactive white noise on the first night, and will switch the machine setting the following day. Devices will be programmed to turn on at 10 PM and off at 6 AM automatically. Decibel level (the machine has 10 preset decibel settings) and start/stop times will be programmed using the manufacturer's smartphone application. One smartphone or tablet (available from prior studies at SRTI) will be assigned to each white noise device, password protected, and stored with the device in the unblinded study staff member's office. The noise level chosen for control (or the inactive white noise) is below that of the background noise of the hospital and should theoretically not have any impact on sound level changes ≥ 17.5 dB (Fig. 3), but will help maintain blinding of staff, participants, and researchers.
Methods (Measurement of outcomes and covariates): Objectively measured sleep metrics will be obtained from actigraphy devices. These include (over the 10PM-6AM period) total sleep time, sleep fragmentation (using mean/median sleep bout length), and number of nighttime awakenings. The investigators will also measure total sleep duration in each 24-hour period. Subjective sleep will be measured using the validated Richards Campbell Sleep Questionnaire (RCSQ). Delirium will be measured twice daily using the Confusion Assessment Method (CAM). AM blood pressure and glucose readings (for diabetic/prediabetic patients) will be obtained from the EMR. Pain scores and opioid administration will also be extracted from the EMR. Pertinent covariates will include age, comorbidities (using Charlson comorbidity index), baseline cognitive status (MoCA assessment), and severity of illness as measured by the highest Modified Early Warning System (MEWS) score for each patient.
Statistical analysis plan: This power analysis is conducted based on a change in sleep fragmentation (as measured by sleep bout length, Fig. 1). The investigators previously found that a 2.5-minute difference in mean sleep bout length between delirious vs. non-delirious patients,8 suggesting that a difference of this magnitude could have clinical significance. Using these prior data, the investigators calculated an effect size (Cohen's d coefficient) of 0.58. The investigators subsequently used G-Power (v. 3.1) software to calculate power using the following parameters: 1) Difference between two dependent means (matched pairs), 2) 2-tailed t-test, 3) P-value (alpha) <0.05), and power of 90%. Based on these calculations, the investigators expect a total sample size of 34 individuals. Expecting a 20% attrition rate (including early/unexpected discharges, technical error, or patient dropout), the investigators conservatively aim to enroll 45 patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
White Noise, Sleep, Sleep Fragmentation, Sleep Duration
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Night A active white noise
Arm Type
Experimental
Arm Description
Patients receiving active level of white noise on night A
Arm Title
Night B inactive white noise
Arm Type
Sham Comparator
Arm Description
Patients will receive a lower Level of white noise on night B. Termed "inactive," because do not expect the level to have a noticeable change in sound level changes, and thus sleep.
Intervention Type
Device
Intervention Name(s)
Active white noise
Intervention Description
Active white noise of 57 dB - 60 dB from 10 pm to 6 am
Intervention Type
Device
Intervention Name(s)
Inactive white noise
Other Intervention Name(s)
Sham comparator
Intervention Description
Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
Primary Outcome Measure Information:
Title
Sound level changes ≥ 17.5 dB
Description
Change in sound level changes ≥ 17.5dB between inactive and active white noise intervention. This will be using sound level measurements obtained from sound meters placed in patient rooms
Time Frame
72 hours
Title
Sleep duration
Description
Measured between patients receiving active vs. inactive white noise in minutes using wrist-worn actigraphy devices
Time Frame
72 hours
Title
Sleep fragmentation
Description
Measured using mean and median sleep bout duration from actigraphy devices in patients receiving active vs. inactive white noise.
Time Frame
72 hours
Title
Subjective sleep quality
Description
Measured using Richards Campbell Sleep Questionnaire. Assesses subjective sleep in patients who received active white noise. vs. inactive white noise.
Time Frame
72 hours
Secondary Outcome Measure Information:
Title
Delirium Incidence
Description
Measured using bCAM. Comparing rates of delirium incidence between patients receiving active vs. inactive white noise.
Time Frame
72 hours
Title
Morning blood glucose
Description
Measured using morning metabolic panels OR point-of-care glucose testing.
Time Frame
72 hours
Title
Morning blood pressure reading
Description
Measured using standard of care vital signs, both systolic and diastolic measurements.
Time Frame
72 hours
Title
Delirium incidence based on sleep fragmentation
Description
Measured using bCAM. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have a higher incidence of delirium compared to those with lower levels of sleep fragmentation.
Time Frame
72 hours
Title
Morning blood pressure based on sleep fragmentation
Description
Measured using standard morning vital signs. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have higher systolic/diastolic blood pressure readings compared to those with lower levels of sleep fragmentation.
Time Frame
72 hours
Title
Morning blood glucose based on sleep fragmentation
Description
Measured using standard morning metabolic panel OR point-of-care glucose testing. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have higher morning blood glucose readings compared to those with lower levels of sleep fragmentation.
Time Frame
72 hours
Title
Opioid use
Description
Measured using morphine milligram equivalent totals over the white noise testing period. In a secondary analysis, the investigators will test whether those individuals with higher sleep fragmentation, as measured by actigraphy, will have more opioid use compared to those with lower levels of sleep fragmentation.
Time Frame
72 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Over 18 years old
Admitted to inpatient internal medicine service for at least 3 nights
Exclusion Criteria:
-
12. IPD Sharing Statement
Learn more about this trial
Sleepless at Scripps: An Inpatient White Noise Study
We'll reach out to this number within 24 hrs